Merck Receives European Approval for Streptococcal Pneumonia Vaccine

MT Newswires Live03-26

Merck (MRK) said Wednesday that the European Commission has approved its drug Capvaxive for immunization against invasive disease and pneumonia caused by streptococcus in people aged 18 years or older.

The specific indication for the drug applies to 22 streptococcus pneumoniae serotypes responsible for the majority of invasive pneumococcal disease cases, the company said.

The approval is based on safety and efficacy data from two phase 3 clinical trials and follows a positive recommendation in January from the European Medicines Agency's Committee for Medicinal Products for Human Use, the company said.

The drug was approved in the US and Canada last year and in Australia in January, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment